OBJECTIVE To determine whether the availability of on-site catheterisation and revascularisation facilities influenced hospital management and outcome of patients with acute myocardial infarction complicated by cardiogenic shock.
METHODS Patients with acute myocardial infarction were enrolled prospectively in four nationwide surveys during 1992, 1994, 1996, and 1998. The characteristics, management, and outcome of patients with cardiogenic shock were compared between hospitals with on-site catheterisation facilities (group 1; 18 hospitals) and without such facilities (group 2; 8 hospitals).
RESULTS Of 5351 patients with acute myocardial infarction, 254 (4.7%) developed cardiogenic shock. Group 1 patients (n = 186 of 3854; 4.6%) were younger (mean (SD) age, 69.6 (12) v 73.7 (10) years, p = 0.006) and had a lower proportion of women (36% v 52%, p = 0.03) than group 2 (n = 68 of 1243; 5.2%). There was no difference in other characteristics including the use of thrombolysis. Group 1 patients more often underwent coronary angiography (26%v 4%, p < 0.001), angioplasty (21%v 4%, p = 0.002), and intra-aortic balloon counterpulsation (28% v 4%, p < 0.001). Seven day mortality was lower among group 1 than among group 2 patients (61% v 77%, p = 0.02), even after age and sex adjustment (odds ratio (OR) 0.54; 95% confidence interval (CI) 0.28 to 1.02). This outcome benefit persisted at 30 days (74%v 88%, p = 0.01; OR 0.45, 95% CI 0.18 to 0.98), and at 6 months (80% v 90%, p = 0.06; OR 0.57, 95% CI 0.22 to 1.33).
CONCLUSIONS The greater use of invasive and interventional procedures in hospitals with catheterisation facilities is associated with improved survival of patients with acute myocardial infarction complicated by cardiogenic shock. Immediate availability of invasive care facilities will improve the outcome of cardiogenic shock in the community setting.
- percutaneous transluminal coronary angioplasty
- heart failure
- myocardial infarction
- cardiogenic shock
Statistics from Altmetric.com
Immediate aggressive treatment combined with early revascularisation is thought to be associated with greater myocardial salvage and better survival of patients with cardiogenic shock complicating acute myocardial infarction.1 Several non-randomised retrospective observations have suggested that urgent percutaneous transluminal coronary angioplasty (PTCA) reduces mortality in patients with acute myocardial infarction complicated by cardiogenic shock.2-5 The greater use of interventional procedures is thought to be responsible for the improved outcome of cardiogenic shock patients in the USA compared with other countries in certain studies.6
However, the relative benefit of interventional procedures in cardiogenic shock in a community setting—in which access to a catheterisation facility and operator expertise is less uniform than in a trial setting—is still unknown.7 This question has important medical, organisational, cost, and training implications. We therefore performed the present study to determine the effect of the availability of on-site catheterisation facilities on the treatment and outcome of patients with cardiogenic shock in a broad spectrum of hospital settings, ranging from rural community hospitals to large tertiary centres. Four national Israeli surveys conducted in 1992, 1994, 1996, and 1998 enrolled all patients with acute myocardial infarction admitted to coronary care units (CCU). We examined this unselected nationwide cohort to determine whether the availability of on-site catheterisation and revascularisation facilities influenced the hospital management and outcome of patients with acute myocardial infarction complicated by cardiogenic shock.
Patients admitted to all 26 CCUs in Israel were prospectively enrolled in four national surveys which were conducted in January and February of 1992 (25 CCUs), January and February of 1994 (25 CCUs), January and February and May to July of 1996 (26 CCUs), and January and February of 1998 (26 CCUs). Details of the registry protocol have been described previously.8 Briefly, the patients' demographic data, medical history, hospital management and complications, and 30 day and six month follow up were recorded prospectively on a predefined survey form.
The medical records of all patients in Killip class IV on admission or with a recorded hospital diagnosis of cardiogenic shock were reviewed by two of the authors (IMB and JL), in order to validate the diagnosis of cardiogenic shock at any time during the hospitalisation and to exclude other causes of shock. The time of shock onset was analysed relative to the hospital admission. The onset of shock before admission or upon arrival at the hospital was regarded as time zero.
Patients were admitted to the nearest available hospital and were referred for invasive cardiac procedures at the discretion of the attending physician. Success of the procedure was determined by the operating physician. Special attention was given to verifying that patients who underwent invasive procedures did so during the shock and not after recovery. All surviving patients were seen or contacted by telephone at 30 days. Six month mortality data were obtained from records of the Ministry of Internal Affairs.
Patients were divided into two groups: those admitted to the 18 hospitals with on-site catheterisation facilities and those admitted to the eight hospitals without catheterisation facilities. Clinical characteristics and outcome were compared retrospectively between the defined groups.
CARDIOGENIC SHOCK CRITERIA
Cardiogenic shock criteria were modified from the SHOCK (should we emergently revascularise occluded coronaries for cardiogenic shock?) trial9 and the GUSTO-I (global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries) trial,4 and included patients with signs predominantly of severe left ventricular dysfunction: systolic blood pressure of 90 mm Hg or less for more than one hour despite a fluid challenge, together with clinical signs of tissue hypoperfusion. Among patients who were monitored with a pulmonary artery catheter, cardiogenic shock criteria included a cardiac index of < 2.2 l/min/M and a pulmonary capillary wedge pressure > 18 mm Hg. Patients in shock because of correctable brady- or tachyarrhythmias or rupture of the left ventricular free wall, interventricular septum, or papillary muscle were excluded from the analysis.
Statistical analysis was performed using SAS software.10 Continuous variables are expressed as mean (SD), or as median (range) where appropriate, and differences were calculated by a two tailed t test or Wilcoxon rank-sum test. Differences between categorical data were analysed by the χ2 test, and a probability value of p < 0.05 was considered significant. Kaplan–Meier survival curves were constructed using the SAS Lifetest procedure.
Multivariate logistic regression analyses were performed to assess the independent effect of different variables on outcome using the SAS Logistic procedure. To ascertain whether there was an independent association between the availability of catheterisation facilities and invasive resource utilisation and outcome, a multivariate logistic regression analysis was done using the SAS Logistic procedure. Additionally, a multivariate model adjusting for age and sex was conducted in order to assess the independent effect of PTCA on mortality.
Of the 5351 patients with acute myocardial infarction admitted to the 26 CCUs during the four national surveys, 254 (4.7%) had a confirmed diagnosis of cardiogenic shock. The mean (SD) age of these 254 patients was 71 (12) years, and 103 (43.5%) of them were women.
Of the 3854 patients admitted to 18 hospitals with on-site catheterisation facilities, 186 (4.6%) had cardiogenic shock. Among the 1243 patients admitted to eight hospitals without catheterisation facilities, 68 (5.2%) had cardiogenic shock (p = 0.4).
Table 1 compares clinical characteristics of the two groups. Patients admitted to hospitals with catheterisation facilities were younger (69.2 (12) v 73.7 (10) years, p = 0.005) and the proportion of women was lower (37%v 52%, p = 0.03). Other baseline characteristics were similar. Median time from admission to shock evolution was similar in the two groups, and a similar proportion of patients were already in cardiogenic shock on admission (57%v 54%, respectively). The clinical characteristics of the patients in the two groups were comparable, including infarct location and peak creatine phosphokinase levels.
The incidence of in-hospital complications was similar (table 1), including rates of atrioventricular block events, recurrent ischaemia, and reinfarction.
No difference was found in the use of drugs and thrombolysis (30%v 38%, p = 0.2) between the patients admitted to hospitals with and without catheterisation facilities (table 2).
Diagnostic coronary angiography was performed in 49 (26%) of the patients treated in hospitals with catheterisation facilities and in three (4%) of the patients treated in hospitals without such facilities (p < 0.001, table 2). Of the patients selected for coronary angiography, three vessel disease was documented in 21 patients, left main coronary artery disease in seven, two vessel disease in 10, and single vessel disease in 14.
Revascularisation and invasive procedures
Patients admitted to hospitals with on-site catheterisation facilities more often underwent invasive procedures, and 39 patients (21%) were referred for PTCA (table 2). Of these, 34 (87%) underwent primary PTCA, and five underwent rescue PTCA. The PTCA success rate in this group was 80%. Patients admitted to hospitals without catheterisation facilities were less likely to undergo PTCA (p = 0.002); one patient underwent rescue PTCA and two were referred for primary PTCA (table 2). All of these patients were treated with an intra-aortic balloon pump (IABP). IABP was used more often among patients admitted to hospitals with catheterisation facilities (28%v 4%, p < 0.001).
ASSOCIATION BETWEEN CATHETERISATION FACILITIES AND OUTCOME
These results are shown in table 3 and fig 1. Overall seven day mortality for all patients with cardiogenic shock was 65%. Patients treated in hospitals with on-site catheterisation facilities experienced lower seven day (61% v 77%, p = 0.02), 30 day (74% v 88%, p = 0.01), and two month mortality (79% v90%, p = 0.05) compared with patients treated in hospitals without such facilities. This benefit remained significant after adjustment for age and sex, with an odds ratio (OR) of 0.54 (95% confidence interval (CI) 0.28 to 1.02) at seven days, and 0.45 (95% CI 0.18 to 0.98) at 30 days. At the two month (OR 0.56, 95% CI 0.22 to 1.30) and six month follow up (OR 0.57, 95% CI 0.22 to 1.33) the independent association of outcome benefit and availability of on-site catheterisation facilities decreased.
PRIMARY AND RESCUE PTCA
Subgroup analysis of patients from group 1 (hospitals with on-site catheterisation facilities) showed that those who underwent PTCA were significantly younger (61 (12) v 71 (11) years, p < 0.001) and more likely to be male (74%v 61%, p = 0.1) than the remaining patients in that group (table 4). PTCA patients also had lower rates of diabetes mellitus (28% v 42%, p = 0.1) and were less likely to have a history of hypertension (26%v 53%, p = 0.002) and previous myocardial infarction (29% v 41%, p = 0.1), but were more likely to smoke (36% v 16%, p = 0.007). Consequently, as shown in table 5, the seven day (26%v 70%), 30 day (39%v 83%), and six month mortality rates (46%v 88%) were significantly lower among patients selected for PTCA than among those not selected (p < 0.0001). This benefit persisted after adjustment for age, sex, and history of hypertension for mortality after seven days (OR 0.15, 95% CI 0.06 to 0.34), at 30 days (OR 0.14, 95% CI 0.06 to 0.32), and within six months (OR 0.14, 95% CI 0.06 to 0.33). For the nine patients in whom patency of the infarct related artery was not achieved during PTCA, mortality was significantly higher at all follow up end points and was 100% at 30 days (table 5). Patients who were treated with IABP experienced lower seven day (38%v 69%, p < 0.001) and six month mortality (63% v 86%, p < 0.001) than patients who were not treated in this way. The survival benefit associated with IABP remained significant at six months after adjustment for age and sex (OR 0.39, 95% CI 0.17 to 0.85).
The major finding of our study is that mortality after acute myocardial infarction complicated by cardiogenic shock is lower in hospitals with catheterisation facilities than in hospitals without such facilities. The greater use of invasive and interventional procedures in hospitals with catheterisation facilities is associated with improved survival of patients with acute myocardial infarction complicated by cardiogenic shock.
The results of our study are consistent with the findings of Holmes and colleagues from the GUSTO-I trial.6 They found an improved 30 day outcome of cardiogenic shock patients in the USA compared with other countries, and suggested that this advantage might be related to the frequent use of invasive interventions in US patients. Our findings support and extend the observation of the GUSTO-I investigators and indicate that the benefits of catheterisation facilities are also present in a non-selected patient population. Compared with the GUSTO-I results, our patients had a higher percentage of cardiogenic shock on admission (56% v 11% among GUSTO-1 patients) and were more likely to have adverse prognostic factors such as older age (70 v 68 years), more women (41% v 39%), and a higher prevalence of diabetes mellitus (41% v 19%) and previous infarction (38% v 25%).4 6These differences, which emphasise the fact that our population was unselected, may also partially explain the higher mortality in our study compared with previous reports.4 6
The prospective randomised SHOCK trial1 evaluated the effect of early revascularisation as compared to the initial medical stabilisation in cardiogenic shock. The SHOCK investigators reported that the primary end point—30 day all cause mortality of a subgroup of patients younger than 75 years of age—was significantly reduced by immediate revascularisation. This benefit became significant for all patients six months after they developed shock. The results of this important study suggest a relation between emergency revascularisation and outcome, thus strengthening the findings of the present study: that on-site catheterisation facilities increase the utilisation of such resources and are associated with improved outcome of patients with cardiogenic shock.
Our study confirmed other observations2 3 9 suggesting that patients with cardiogenic shock who were selected for PTCA had better baseline characteristics and improved short and long term outcome compared with patients who were not selected for this treatment. This outcome benefit remained significant even after adjustment for baseline characteristics, and was more significant for patients with successful PTCA or insertion of an IABP.
Our findings should be interpreted with caution as this was a post-hoc analysis and therefore subject to the limitations of such studies. Other factors such as nursing skills, hospital volume, and operator experience might have influenced the outcome. The decline in the benefit associated with treatment in hospitals with catheterisation facilities by six months may be related to the relatively low rates of invasive therapeutic intervention performed in these hospitals (19% PTCA and 24% IABP), compared with the higher rates in previous reports (up to 48% PTCA and up to 35% IABP).1 6 9
CONCLUSIONS AND IMPLICATIONS
Despite the availability of on-site catheterisation facilities and improved survival, mortality from cardiogenic shock remains high. It is possible that the impact of on-site catheterisation facilities on the outcome of cardiogenic shock might have been made more significant by increasing the proportion of patients transferred for immediate PTCA and by the use of stents and IIb/IIIa receptor antagonists in high risk coronary interventions. Substantial improvements in the management of cardiogenic shock will result from organisational and logistic changes which may lead to rapid and more widespread use of invasive treatments in these high risk patients with acute myocardial infarction.
This work formed part of the MD thesis requirements of IMB at the Faculty of Health Sciences, Ben-Gurion University. The work was supported by grants Nos 95-294 and 98-414 from the United States–Israel Binational Science Foundation (BSF), and grant No 3619 from the Ministry of Health Sciences.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.